🙌Game-changing real-world data from SWEDEHEART!
📰Leosdottir et al., JACC 2024 https://t.co/AzeX7q4KlY
Title: Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes
👩🦰🧑🦰Population: >71,000 post-MI patients on high-intensity statins
Groups:
1️⃣ Ezetimibe within 6 months of MI
2️⃣ Ezetimibe 6–12 months post-MI
3️⃣ No ezetimibe
🤩Findings: Early ezetimibe → ↓ 22% in MACE (HR 0.78 [0.70–0.86]) vs. late initiation
☝️Compared to no ezetimibe → HR 0.85 [0.79–0.91] ☝️NNT = 53 to prevent 1 MACE with early initiation
☝️Mortality also significantly reduced with early use
👉Delaying ezetimibe after MI = missed opportunity to prevent events.
The message is clear: Start combination lipid-lowering therapy early—not when LDLc remains high, but when risk is high.
@society_eas@ProfKausikRay